Dakota Wealth Management Takes $236,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Dakota Wealth Management acquired a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the fourth quarter, Holdings Channel.com reports. The fund acquired 11,320 shares of the biopharmaceutical company’s stock, valued at approximately $236,000.

A number of other hedge funds have also recently modified their holdings of CPRX. GAMMA Investing LLC grew its holdings in shares of Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 681 shares during the period. nVerses Capital LLC purchased a new stake in Catalyst Pharmaceuticals in the third quarter valued at $50,000. Larson Financial Group LLC lifted its stake in shares of Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 2,994 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth $134,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter worth about $151,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Up 0.2 %

CPRX stock opened at $22.55 on Monday. The business has a 50 day moving average price of $21.79 and a 200 day moving average price of $20.52. The stock has a market cap of $2.69 billion, a price-to-earnings ratio of 19.11, a PEG ratio of 2.28 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $13.12 and a fifty-two week high of $24.27.

Wall Street Analyst Weigh In

CPRX has been the topic of a number of recent analyst reports. Truist Financial upped their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. StockNews.com cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 11th. Stephens assumed coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an “overweight” rating and a $35.00 target price on the stock. HC Wainwright increased their price objective on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Finally, Bank of America reissued a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $32.86.

Insider Activity

In related news, insider Steve Miller sold 50,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the sale, the insider now directly owns 686,996 shares of the company’s stock, valued at $15,065,822.28. This represents a 6.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gary Ingenito sold 12,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now directly owns 51,391 shares in the company, valued at approximately $1,167,603.52. This trade represents a 18.93 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 79,500 shares of company stock worth $1,754,140. Corporate insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.